AFN50 is an mRNA-based in vivo CAR-T program designed to directly program and activate T cells in vivo for the selective elimination of pathogenic immune cells in autoimmune diseases. The program is currently being evaluated in investigator-initiated trials (IIT).

AFN52 is an in vivo CAR-T program targeting solid tumors, leveraging AlphaNa’s proprietary immune cell programming and delivery platform to generate functional CAR-T cells directly in vivo without ex vivo manipulation. The program is currently in IIT studies.

AFN56 is a first-in-class in vivo Tol-APC program that directly generates tolerogenic antigen-presenting cells in vivo to induce immune tolerance and suppress aberrant immune responses in autoimmune diseases. The program is currently in IIT studies.

AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.

AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.

AFN02 is a prophylactic mRNA vaccine targeting respiratory syncytial virus (RSV) and is currently in Phase II clinical development. It represents one of the most advanced and potentially first-in-class mRNA RSV vaccine programs in China.

AFN12 is an mRNA vaccine candidate for the prevention of Herpes Zoster and is currently in Phase I clinical development, further expanding the company’s portfolio in prophylactic vaccines.